Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05297448 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Study acronym: RED-C-3132
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 10, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study title shortened, about 4 wordsv10 See this version in full on ClinicalTrials.gov ↗
  2. Primary endpoint revised Secondary endpoints revised (3)v9 Show 1 more changeShow less
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  3. Primary and study completion dates: Jan 2025 to Jan 2026 Trial status: Recruiting to Active, Not Recruiting · Study sites: 17 to 188v8 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 17 to 188
  4. Study sites: 5 to 17v7
  5. Study sites: 61 to 5 Eligibility criteria shortened, about 21 words · Secondary endpoints: 1 to 3v6 Show 2 more changesShow less
    • Eligibility criteria shortened, about 21 words
    • Secondary endpoints: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 1 to 61 Eligibility criteria shortened, about 743 wordsv5 Show 1 more changeShow less
    • Eligibility criteria shortened, about 743 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jul 2022 to Aug 3, 2022v4 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2022 to Aug 3, 2022
  3. Start date: Jun 2022 to Jul 2022v3
  4. Start date: Apr 2022 to Jun 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Trial Details
NCT Number NCT05297448
Lead Sponsor Bausch Health Americas, Inc.
Conditions Hepatic Encephalopathy
Enrollment 466 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov